Fingerprint
Dive into the research topics of 'Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes
Ken Lee Chin, Richard Ofori-Asenso, Si Si, Thomas R Hird, Dianna J Magliano, Sophia Zoungas, Danny Liew
Research output: Contribution to journal › Article › peer-review
21
Citations
(SciVal)